RhumbLine Advisers
BLTE

RhumbLine Advisers’s Belite Bio BLTE Stock Holding History

RhumbLine Advisers’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,435
Closed -$95K – 4155
2025
Q1 		$95K Hold
1,435
– – ﹤0.01% 3409
2024
Q4 		$90.5K Hold
1,435
– – ﹤0.01% 3505
2024
Q3 		$67.3K Buy
+1,435
New +$69.6K ﹤0.01% 3620

Other funds holding BLTE

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RhumbLine Advisers's BLTE Position: Q2 2025 in Review

RhumbLine Advisers sold out of Belite Bio (BLTE) in Q2 2025, closing a stake of 1,435 shares — an estimated $95K sold.

RhumbLine Advisers first reported a position in BLTE in Q3 2024 and held it in 3 quarters. The position peaked at $95K in Q1 2025. 18 funds tracked by Wall St. Rank hold BLTE as of Q2 2025.

  • RhumbLine Advisers reported no remaining Belite Bio position as of Q2 2025 after selling out during the quarter.
  • RhumbLine Advisers sold 1,435 Belite Bio shares in Q2 2025, an estimated $95K.
  • RhumbLine Advisers first reported a position in Belite Bio in Q3 2024 and held it in 3 quarters.
  • RhumbLine Advisers's Belite Bio position peaked at $95K in Q1 2025.
  • 18 funds tracked by Wall St. Rank held Belite Bio as of Q2 2025.

Based on RhumbLine Advisers's 13F filing for Q2 2025, filed 12 Aug 2025.